Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts
Open accessPublished version of a preprint
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
SF3B1 mutations, which occur in 20% of patients with myelodysplastic syndromes (MDS), are the hallmarks of a specific MDS subtype, MDS with ringed sideroblasts (MDS-RS), which is characterized by the accumulation of erythroid precursors in the bone marrow and primarily affects the elderly population. Here, using single-cell technologies and functional validation studies of primary SF3B1-mutant MDS-RS samples, we show that SF3B1 mutations lead to the activation of the EIF2AK1 pathway in response to heme deficiency and that targeting this pathway rescues aberrant erythroid differentiation and enables the red blood cell maturation of MDS-RS erythroblasts. These data support the development of EIF2AK1 inhibitors to overcome transfusion dependency in patients with SF3B1-mutant MDS-RS with impaired red blood cell production. Significance: MDS-RS are characterized by significant anemia. Patients with MDS-RS die from a shortage of red blood cells and the side effects of iron overload due to their constant need for transfusions. Our study has implications for the development of therapies to achieve long-lasting hematologic responses. This article is highlighted in the In This Issue feature, p. 476
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“other TKI-resistance hits, such as EIF2AK1 and CCDC101, are key regulatory factors of erythroid differentiation of HSCs.”
From Integrated drug profiling and CRISPR screening identify BCR::ABL1-independent vulnerabilities in chronic myeloid leukemia (2024) · cites this paper as [49]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424 · cited 1×
“To induce erythroid differentiation, parental and SF3B1 K700E K562 cells were treated with 30 μ mol/L hemin (catalog number”
Autophagy and the Integrated Stress Response
Kroemer, G., Mariño, G., & Levine, B. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.023 · Cited by 3,506
Frequent pathway mutations of splicing machinery in myelodysplasia
Yoshida, K., Sanada, M., Shiraishi, Y., Nowak, D., Nagata, Y., Yamamoto, R., Sato, Y., Sato-Otsubo, A., Kon, A., Nagasaki, M., et al. (2011) · Nature · doi:10.1038/nature10496 · Cited by 2,029 · cited 1×
“…in different hematopoietic cell types (3), SF3B1 MT preferentially deregulate erythroid progenitors and are hallmarks of a subtype of MDS characterized by the accumulation of ringed sideroblasts (RS) in the bone marrow (BM), MDS-RS (4– by which SF3B1 MT modulate RNA splicing in MDS-RS MT (8–12).”
Single-cell transcriptional diversity is a hallmark of developmental potential
Gulati, G. S., Sikandar, S. S., Wesche, D. J., Manjunath, A., Bharadwaj, A., Berger, M. J., Ilagan, F., Kuo, A. H., Hsieh, R. W., Cai, S., et al. (2020) · Science · doi:10.1126/science.aax0249 · Cited by 1,571
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
Papaemmanuil, E., Cazzola, M., Boultwood, J., Malcovati, L., Vyas, P., Bowen, D., Pellagatti, A., Wainscoat, J. S., Hellstrom-Lindberg, E., Gambacorti-Passerini, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103283 · Cited by 1,222
Transcriptional Addiction in Cancer
Bradner, J. E., Hnisz, D., & Young, R. A. (2017) · Cell · doi:10.1016/j.cell.2016.12.013 · Cited by 1,194
The eIF2α/ATF4 pathway is essential for stress-induced autophagy gene expression
B’chir, W., Maurin, A.-C., Carraro, V., Averous, J., Jousse, C., Muranishi, Y., Parry, L., Stepien, G., Fafournoux, P., & Bruhat, A. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt563 · Cited by 1,162
Corces, M. R., Buenrostro, J. D., Wu, B., Greenside, P. G., Chan, S. M., Koenig, J. L., Snyder, M. P., Pritchard, J. K., Kundaje, A., Greenleaf, W. J., et al. (2016) · Nature Genetics · doi:10.1038/ng.3646 · Cited by 1,151
Transcriptional Heterogeneity and Lineage Commitment in Myeloid Progenitors
Paul, F., Arkin, Y., Giladi, A., Jaitin, D. A., Kenigsberg, E., Keren-Shaul, H., Winter, D., Lara-Astiaso, D., Gury, M., Weiner, A., et al. (2015) · Cell · doi:10.1016/j.cell.2015.11.013 · Cited by 1,082 · cited 1×
“…MDS-RS Ery/Mk cells had higher expression of KLF1 ( P = 0) and lower expression of FLI1 ( P 4.68 − ), the two major regulators of Ery and Mk differentiation, respectively (17), which suggests that these and S1D), which underscores the state of metabolic activation in SF3B1 -mutant cells .”
InfluentialHuman haematopoietic stem cell lineage commitment is a continuous process
Velten, L., Haas, S. F., Raffel, S., Blaszkiewicz, S., Islam, S., Hennig, B. P., Hirche, C., Lutz, C., Buss, E. C., Nowak, D., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3493 · Cited by 925
Research works printed but not linked: 1
- Berastegui N, Ainciburu M, Romero JP, Alfonso-Pierola A, Philippe C, Vilas-Zornoza A,. Transcriptional regulation of HSCs in aging and MDS reveals DDIT3 as a potential driver of transformation. bioRxiv 2021: 2021.09.08.459384.
Cited by
Normal and dysregulated crosstalk between iron metabolism and erythropoiesis
Ginzburg, Y. Z., An, X., Rivella, S., & Goldfarb, A. N. (2023) · eLife · doi:10.7554/elife.90189 · Cited by 51
Jiang, M., Chen, M., Liu, Q., Jin, Z., Yang, X., & Zhang, W. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1116438 · Cited by 36
“Notably, downregulation of EIF2AK1 signaling following the application of hypomethylating agent (HMA) intervention significantly increased the expression of mitochondrial heme biosynthetic enzymes and iron transport proteins and improved terminal differentiation of SF3B1 mutant MDS-RS erythrocytes, suggesting that the…”
BackgroundChen, J.-J. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.108494 · Cited by 22
“Myelodysplastic syndromes with ringed sideroblast (MDS-RS) are hematological malignancies with splicing factor SF3B1 mutations often occurring in elderly populations (134, 135).”
Bravo, G. M., Thongon, N., Rodríguez‐Sevilla, J. J., Ma, F., Gañán‐Gómez, I., Yang, H., Kim, Y. J., Ademà, V., Wildeman, B., Tanaka, T. N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101585 · Cited by 17
Self-citationAdnan Awad, S., Dufva, O., Klievink, J., Karjalainen, E., Ianevski, A., Pietarinen, P., Kim, D., Potdar, S., Wolf, M., Lotfi, K., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101521 · Cited by 14
“47 Inaddition, otherTKI-resis-tance hits, such as EIF2AK1 and CCDC101 , are key regulatory factors of erythroid differentiation of HSCs. 48,49 On the other hand, potential TKI-sensitization hits included RAB10 , IGF1R , and YBX1 genes.”
Metadata
- Authors
- Adema, V., Ma, F., Kanagal-Shamanna, R., Thongon, N., Montalban-Bravo, G., Yang, H., Peslak, S. A., Wang, F., Acha, P., Sole, F., Lockyer, P., Cassari, M., Maciejewski, J. P., Visconte, V., Gañán-Gómez, I., Song, Y., Bueso-Ramos, C., Pellegrini, M., Tan, T. M., Bejar, R., Carew, J. S., Halene, S., Santini, V., Al-Atrash, G., Clise-Dwyer, K., Garcia-Manero, G., Blobel, G. A., & Colla, S.
- Affiliations
- 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- University of Michigan (US)
- 3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- The University of Texas MD Anderson Cancer Center (US)
- Children's Hospital of Philadelphia (US)
- Universitat Autònoma de Barcelona (ES)
- 7MDS Research Group, Josep Carreras Leukaemia Research Institute, Universitat Autonoma de Barcelona, Badalona, Spain.
- Azienda Ospedaliero-Universitaria Careggi (IT)
- Cleveland Clinic (US)
- Sun Yat-sen University (CN)
- University of California, Los Angeles (US)
- University of California San Diego (US)
- University of Arizona Cancer Center (US)
- Yale Cancer Center (US)
- 15Department of Stem Cell Transplantation and Hematopoietic Biology and Malignancy, The University of Texas MD Anderson Cancer Center, Houston, Texas.
- Corresponding author
- Colla, Simona
- ORCID
- Adema, Vera
- Ma, Feiyang
- Kanagal-Shamanna, Rashmi
- Thongon, Natthakan
- Montalban-Bravo, Guillermo
- Yang, Hui
- Peslak, Scott A.
- Wang, Feng
- Acha, Pamela
- Sole, Francesc
- Lockyer, Pamela
- Cassari, Margherita
- Maciejewski, Jaroslaw P.
- Visconte, Valeria
- Gañán-Gómez, Irene
- Song, Yuanbin
- Bueso-Ramos, Carlos
- Pellegrini, Matteo
- Tan, Tuyet M.
- Bejar, Rafael
- Carew, Jennifer S.
- Halene, Stephanie
- Santini, Valeria
- Al-Atrash, Gheath
- Clise-Dwyer, Karen
- Garcia-Manero, Guillermo
- Blobel, Gerd A.
- Colla, Simona
- Venue
- Blood Cancer Discovery
- Published
- 2022-08-03
- Volume
- 3
- Issue
- 6
- Pages
- 554-567
- ISSN
- 2643-3230 (ISSN-L)
- 2643-3249
- PMC
- PMC9894566
- OpenAlex
- W4289800060
- Cited by
- 20
- References
- 44
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 5 · 2023: 5
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Blood Cancer Discovery (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, cc-by-nc-nd)
- Funders
- University of Texas MD Anderson Cancer Center (P50 CA100632)
- Division of Diabetes, Endocrinology, and Metabolic Diseases (5U54DK106857)
- National Cancer Institute (P30 CA16672)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Research and Splicing
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- SF3B1 mutation, heme deficiency, erythroid differentiation, erythropoiesis, transfusion dependence, iron overload, anemia, erythroblasts
- MeSH terms
- RNA Splicing Factors, Aged, Humans, Myelodysplastic Syndromes, Phosphoproteins, Signal Transduction, Erythroid Precursor Cells, eIF-2 Kinase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. https://app.cochat.ai/papers/10.1158/2643-3230.bcd-21-0220
- The paper
- Adema, V., Ma, F., Kanagal-Shamanna, R., Thongon, N., Montalban-Bravo, G., Yang, H., Peslak, S. A., Wang, F., Acha, P., Sole, F., Lockyer, P., Cassari, M., Maciejewski, J. P., Visconte, V., Gañán-Gómez, I., Song, Y., Bueso-Ramos, C., Pellegrini, M., Tan, T. M., . . . Colla, S. (2022). Targeting the EIF2AK1 Signaling Pathway Rescues Red Blood Cell Production in SF3B1 -Mutant Myelodysplastic Syndromes With Ringed Sideroblasts. Blood Cancer Discovery. https://doi.org/10.1158/2643-3230.bcd-21-0220
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.